# EDGAR Filing Document

**Accession Number:** 0001309082
**File Stem:** 0001477932-25-004885
**Filing Date:** 2025-7
**Character Count:** 19174
**Document Hash:** cee988f21228dff014e3e4fb52d36fcb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-25-004885.hdr.sgml**: 20250702

**ACCESSION NUMBER**: 0001477932-25-004885

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20250701

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250702

**DATE AS OF CHANGE**: 20250702

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CAMBER ENERGY, INC.
- **CENTRAL INDEX KEY:** 0001309082
- **STANDARD INDUSTRIAL CLASSIFICATION:** CRUDE PETROLEUM & NATURAL GAS [1311]
- **ORGANIZATION NAME:** 01 Energy & Transportation
- **EIN:** 202660243
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32508
- **FILM NUMBER:** 251098357

**BUSINESS ADDRESS:**
- **STREET 1:** 15915 KATY FREEWAY
- **STREET 2:** SUITE 450
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77094
- **BUSINESS PHONE:** (281) 404-4387

**MAIL ADDRESS:**
- **STREET 1:** 15915 KATY FREEWAY
- **STREET 2:** SUITE 450
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77094

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LUCAS ENERGY, INC.
- **DATE OF NAME CHANGE:** 20060620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Panorama Investments Corp
- **DATE OF NAME CHANGE:** 20041118

?xml version='1.0' encoding='ASCII'? cei_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **<u>July 1, 2025</u>**

---

| |
|:---|
| **Camber Energy, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-32508** | **20-2660243** |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **12 Greenway Plaza, Suite 1100, Houston, Texas** | **77046** |
| (Address of principal executive offices) | (Zip Code) |

---

**(Registrant's telephone number, including area code): <u>(281) 404-4387</u>**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act: None.**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events.**

On January 21, 2025, Camber Energy, Inc. ("Camber" or the "Company") announced that its indirect majority-owned subsidiary, Viking Ozone Technology, LLC ("VOT"), shipped VOT's *VKIN-300* waste treatment unit (the "VKIN-300 Unit") to France to undergo procedures to obtain official certification of compliance with French Standard NFX 30-503, regarded as one of the world's strictest standards for waste decontamination equipment.

In connection with the proposed certification process, various tests were performed on or in respect of the VKIN-300 Unit in May and June 2025. On July 1, 2025, VOT received a report (the "Lab Report") from Laboratoire Hygiène Hospitalière CHU Clermont-Fd ("LHH"), an independent lab, summarizing the testing procedures and associated results, and concluding as follows

· French Version: "*Les tests réalisés conformément à la norme NFX 30503-1 par le laboratoire démontrent que l'appareil de prétraitement des déchets VKIN 300 répond aux spécifications de cette norme.*"

· English Translation (translated through DeepL Pro Ultimate): "*The tests carried out in accordance with standard NFX 30503-1 by the laboratory demonstrate that the VKIN 300 waste pre-treatment unit meets the specifications of this standard."*

The foregoing description of the Lab Report does not purport to be complete and is qualified in its entirety by reference to the full text of the Lab Report, the French version of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, and the English translated version of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The Lab Report, along with other reports and documentation, will be submitted to the applicable agency requesting formal certification of the VKIN-300 Unit for use in France. Given the conclusion of the Lab Report it is likely the certification will be obtained but there are no assurances of such result.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](cei_ex991.htm) | [Lab Report, the French version, dated July 1, 2025.](cei_ex991.htm) |
| [99.2](cei_ex992.htm) | [Lab Report, the English translated version, dated July 1, 2025.](cei_ex992.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CAMBER ENERGY, INC.**  | **CAMBER ENERGY, INC.**  |
| Date: July 2, 2025 | By:  | */s/ James A. Doris*  |
|  | Name: | James A. Doris  |
|  | Title: | Chief Executive Officer  |

---

## Exhibit 99.1

**EXHIBIT 99.1**

![](cei_ex991img37.jpg)

**Rapport d'essais de l'appareil de prétraitement des déchets VKIN 300 selon les préconisations de la norme NFX 30503-1**

**Laboratoire Hygiène Hospitalière**

**CHU Clermont-Ferrand**

**Mai-Juin 2025**

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

➢ **Essais sur la contamination microbienne aérienne (NFX 30503-1 Annexe A1)** 

**Méthodes**

Prélèvement par biocollecteur Sampl'air (AES Laboratoires) étalonné le 20/10/2024.

Volume prélevé par échantillon : 100 litres par impaction sur géloses Trypcase Soy Agar (TSA) (Biomérieux, réf 43011).

Conservation et transports des prélèvements à 4°C jusqu'à mise en incubation (délai < 24h)

Gélose TSA incubée 3 jours à 30°C et 2 jours à 25°C

Expression en unités formant colonies / m<sup>3</sup>, conversion en log<sub>10</sub>.

**Résultats**

Absence de *Staphylococcus* spp, d'entérobactéries, de levures, de *Pseudomonas* spp et autres bacilles à Gram négatif non fermentaires

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

➢ **Essais de traitement sur indicateurs biologiques (NFX 30503-1 Annexe A2)** 

**Méthodes**

<u>Description des porte-germes</u>

Porte-germe constitué de carré de compresses non-tissé (LCH ref 44564 Lot 4500005471)

I. <u>*Bacillus et Aspergillus*</u> 

<u>Numération des suspensions bactériennes et fongiques</u>

- Dilution des suspensions mères jusqu'à 10.-8 pour *Bacillus* et jusqu'à 10.-9 pour *Aspergillus* dans du bouillon tryptone sel

- Etalement de 100 µl des dilutions 10.-5 jusqu'à 10.-8 pour *Bacillus* sur gélose TSA

- Etalement de 100 µl des dilutions 10.-6 jusqu'à 10.-9 pour *Aspergillus* sur gélose Sabouraud (Thermo Scientific réf PO5096A)

- Incubation 48-72 h à 30°C

<u>Dépôt des microorganismes sur les compresses porte-germes</u>

- *Bacillus* : dépôt de 100 µl de la suspension bactérienne

- *Aspergillus* : dépôt de 10 µl de la suspension bactérienne

Ajout de sang de mouton comme substance interférente (Labmedical réf H04F-0817-P-0025) dans la suspension

Inoculation de la suspension par dépôt sur l'ensemble du porte-germe

<u>Après traitement (indicateurs biologiques et courbe D)</u>

Les compresses sont transférées dans des tubes Falcon stériles. On rajoute 3 ml (volume minimum pour que la gaze soit bien imprégnée) de bouillon Tryptone sel dans chaque tube. Vortexer 5 min.

<u>Dilutions des suspensions</u> 

- compresses tube transport : dilution jusqu'à 10-7

- compresses indicateurs biologiques et courbes D : dilution jusqu'à 10-4

- étalement de 100µl des dilutions sur gélose TSA (Sabouraud pour *Aspergillus*). Le reste de l'échantillon pur est ensemencé sur des boites de Petri supplémentaires de façon à analyser l'ensemble de l'échantillon.

- Incubation 48-72h à 30°C

II. <u>*Adenovirus*</u> 

<u>Culture des cellules HeLa</u> 

Le milieu utilisé pour la croissance des cellules est HeLa est le milieu MEM préparé comme suit :

MEM (450 mL) + 10% SVF décomplémenté filtré à 0.22 µm (50 mL) + ATB2x (1mL)

<u>Virus : Human Adenovirus 5 (ATCC VR-5 <sup>TM</sup>)</u> Lot 70053996 Date de validation 26/09/2022

<u>Modalités de culture du virus</u>

Les cellules HeLa sont ensemencées en microplaques 96 puits (Falcon, ref 353072) 48 h avant l'infection.

Les porte-germes sont placés de façon aseptique dans un tube Falcon contenant 3 mL de milieu MEM.

Sonication pendant 1 min (Branson 2510) puis vortex pendant au moins 2 min

Dilution de série 10 en milieu MEM

Inoculation des microplaques avec l'échantillon pur et les dilutions (100 µL par puits, 8 puits par dilution). Le reste de l'échantillon pur est ensemencé sur des puits supplémentaires de façon à analyser l'ensemble de l'échantillon.

Incubation 2h à 37°C en agitation douce puis ajout de 100 µL de milieu MEM.

Incubation à 37° C sous 5% de CO<sub>2</sub>

Lecture de l'effet cytopathogène à 2 et 3 jours post inoculation.

Détermination du titre viral selon la méthode de Spearman Kärber.

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

<u>Références des produits utilisés pour les cultures cellulaires et virales</u> :

MEM avec glutamine (réf Dutscher L0416 – 500)

PBS sans calcium ni magnésium (réf Dutscher L0615 – 500)

Trypsine avec rouge phénol sans calcium ni magnésium (réf Dutscher L0930 – 100)

Sérum de veau fœtal

Antibiotiques Pénicilline Streptomycine Néomycine (réf Sigma P4083)

**Résultats**

![](cei_ex991img10.jpg)

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

![](cei_ex991img38.jpg)

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

![](cei_ex991img11.jpg)

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

➢ **Essais de traitement sur déchets infectieux et essais de reviviscence (NFX 30503-1 Annexe A3)** 

**Méthodes**

<u>Déchets avant traitement</u>

- Peser 5 gr de DASRI

- Ajouter 45 ml de bouillon Tryptone sel (Dutscher réf 693424)

- Vortexer

- Laisser en contact à température ambiante pendant 1h en vortexant régulièrement

- Faire des dilutions jusqu'à 10-7 en bouillon tryptone sel

- Etaler 100 µl des dilutions 10.-4 jusqu'à 10.-7 sur des géloses TSA

- Incuber 48-72h à 30°C

- Numération de la flore bactérienne aérobie revivifiable et recherche de la présence de *Staphylococcus* spp, d'entérobactéries, de levures, de *Pseudomonas* spp et autres bacilles à Gram négatif non fermentaires

<u>Déchets après traitement</u>

- Peser 5 gr de DASRI

- Ajouter 45 ml de bouillon tryptone sel

- Laisser en contact à température ambiante pendant 1h en vortexant régulièrement

- Faire des dilutions de 10.-1 jusqu'à 10.-5 en bouillon tryptone sel

- Etaler 100 µl des 5 dilutions sur des géloses TSA

- Incuber 48-72 h à 30°C

- Numération de la flore bactérienne aérobie revivifiable et recherche de la présence de *Staphylococcus* spp, d'entérobactéries, de levures, de *Pseudomonas* spp et autres bacilles à Gram négatif non fermentaires

**Résultats (7, 8 et 9 mai 2025)**

![](cei_ex991img39.jpg)

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

![](cei_ex991img40.jpg)

![](cei_ex991img41.jpg)

➢ **Essais de granulométrie**![](cei_ex991img17.jpg)

NB : la formule du tableau B5 de l'annexe A de la norme est erronée sur la colonne D (poids du refus) : (C-A)/B est à remplacer par (C-A).

**Conclusion :**

Les tests réalisés conformément à la norme NFX 30503-1 par le laboratoire démontrent que l'appareil de prétraitement des déchets VKIN 300 répond aux spécifications de cette norme.

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

![](cei_ex991img37.jpg)

Pr O Traoré

Essais EC-EFRES 2025 Laboratoire Hygiène Hospitalière CHU Clermont-Fd

## Exhibit 99.2

**EXHIBIT 99.2**

![](cei_ex992img13.jpg)

**Test report for the VKIN 300 waste pre-treatment unit in accordance with NFX 30503-1 standard.**

**Hospital Hygiene Laboratory**

**Clermont-Ferrand University Hospital**

**May-June 2025**

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd

![](cei_ex992img14.jpg)

➢ **Airborne microbial contamination tests (NFX 30503-1 Annex A1)** 

**Methods**

Sampling by Sampl'air biocollector (AES Laboratoires) calibrated on 20/10/2024.

Volume collected per sample: 100 liters by impaction on Trypcase Soy Agar (TSA) (Biomérieux, ref 43011).

Samples stored and transported at 4°C until incubation (< 24h).

TSA agar incubated 3 days at 30°C and 2 days at 25°C

Expression in colony-forming units / m<sup>3</sup>, conversion into log<sub>10</sub>.

**Results**

Absence of *Staphylococcus* spp, enterobacteria, yeasts, *Pseudomonas* spp and other non-fermentative Gram-negative bacilli

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd

![](cei_ex992img15.jpg)

➢ **Treatment tests on biological indicators (NFX 30503-1 Annex A2)** 

**Methods**

<u>Description of germ carriers</u>

Germ carrier consisting of square non-woven compresses (LCH ref 44564 Lot 4500005471)

I. <u>*Bacillus and Aspergillus*</u> 

<u>Counting of bacterial and fungal suspensions</u>

Dilute stock suspensions to 10.-8 for *Bacillus* and 10.-9 for *Aspergillus* in tryptone-salt broth.

- Spread 100 µl of dilutions 10.-5 to 10.-8 for *Bacillus* on TSA agar

- Spread 100 µl of dilutions 10.-6 to 10.-9 for *Aspergillus* on Sabouraud agar (Thermo Scientific ref PO5096A)

- Incubation 48-72 h at 30°C

<u>Deposition of microorganisms on germ-bearing swabs</u>

*-Bacillus*: deposit of 100 µl of bacterial suspension

*-Aspergillus*: deposition of 10 µl of bacterial suspension

Addition of sheep blood as an interfering substance (Labmedical ref. H04F-0817-P-0025) to the suspension

Inoculation of the suspension by depositing it on the entire germ carrier

<u>After treatment (biological indicators and D curve)</u>

The gauze is transferred to sterile Falcon tubes. Add 3 ml (minimum volume to ensure gauze is well impregnated) of Tryptone salt broth to each tube. Vortex for 5 min.

<u>Suspension dilutions</u> 

- transport tube swabs: dilution down to 10-7

- biological indicator swabs and D curves: dilution to 10-4

- spread 100µl of dilutions on TSA agar (Sabouraud for *Aspergillus*). The remainder of the pure sample is inoculated onto additional Petri dishes in order to analyze the entire sample.

- Incubation 48-72h at 30°C

II. *<u>Adenovirus</u>* 

<u>HeLa cell culture</u> 

The medium used for HeLa cell growth is MEM medium prepared as follows:

MEM (450 mL) + 10% decomplemented SVF filtered at 0.22 µm (50 mL) + ATB2x (1mL)

<u>Virus: Human Adenovirus 5 (ATCC VR-5 <sup>TM</sup>)</u> Lot 70053996 Validation date 26/09/2022

<u>Virus culture methods</u>

HeLa cells are seeded in 96-well microplates (Falcon, ref 353072) 48 h prior to infection.

Germ carriers are aseptically placed in a Falcon tube containing 3 mL of MEM medium.

Sonicate for 1 min (Branson 2510), then vortex for at least 2 min.

Series 10 dilution in MEM medium

Inoculation of microplates with pure sample and dilutions (100 µL per well, 8 wells per dilution). The remainder of the pure sample is inoculated into additional wells, so that the whole sample can be analyzed.

Incubate for 2 h at 37°C with gentle agitation, then add 100 µL of MEM medium.

Incubation at 37°C under 5% CO<sub>(2).</sub>

Read cytopathic effect at 2 and 3 days post-inoculation.

Determination of viral titer by Spearman Kärber method.

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd

![](cei_ex992img16.jpg)

<u>References of products used for cell and viral cultures</u>:

MEM with glutamine (Dutscher ref. L0416 - 500)

PBS without calcium or magnesium (ref Dutscher L0615 - 500)

Trypsin with phenol red, calcium- and magnesium-free (Dutscher ref. L0930 - 100)

Fetal calf serum

Antibiotics Penicillin Streptomycin Neomycin (ref Sigma P4083)

**Results**

![](cei_ex992img8.jpg)

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd

![](cei_ex992img17.jpg)

➢ **Treatment tests on infectious waste and reviviscence tests (NFX 30503-1 Annex A3)** 

Methods

<u>Waste before treatment</u>

- Weigh 5 g of HIW

- Add 45 ml Tryptone salt broth (Dutscher ref 693424)

- Vortex

- Leave in contact at room temperature for 1 hour, vortexing regularly

- Make dilutions down to 10-7 in tryptone-salt broth

- Spread 100 µl of dilutions 10.-4 to 10.-7 on TSA agar plates

-Incubate 48-72h at 30°C

- Count the revivifiable aerobic bacterial flora and test for the presence of *Staphylococcus* spp, Enterobacteriaceae, yeasts, *Pseudomonas* spp and other non-fermentative Gram-negative bacilli.

<u>Waste after treatment</u>

- Weigh out 5 g of HIW

- Add 45 ml tryptone-salt broth

- Leave in contact at room temperature for 1 hour, vortexing regularly

- Make dilutions from 10.-1 to 10.-5 in tryptone-salt broth

- Spread 100 µl of the 5 dilutions on TSA agar plates

- Incubate 48-72 h at 30°C

- Count the revivifiable aerobic bacterial flora and test for the presence of *Staphylococcus* spp, Enterobacteriaceae, yeasts, *Pseudomonas* spp and other non-fermentative Gram-negative bacilli.

**Results (May 7, 8 and 9, 2025)**

![](cei_ex992img24.jpg)

![](cei_ex992img25.jpg)

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd

![](cei_ex992img18.jpg)

![](cei_ex992img26.jpg)

➢ **Granulometry tests**![](cei_ex992img12.jpg)

NB: the formula in table B5 of appendix A of the standard is incorrect in column D (reject weight): (C-A)/B should be replaced by (C-A).

**Conclusion:**

The tests carried out in accordance with standard NFX 30503-1 by the laboratory demonstrate that the VKIN 300 waste pre-treatment unit meets the specifications of this standard.

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd

![](cei_ex992img19.jpg)

Pr O Traoré

EC-EFRES 2025 tests Hospital Hygiene Laboratory CHU Clermont-Fd